Equities analysts predict that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce earnings of ($0.15) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Achillion Pharmaceuticals posted earnings of ($0.03) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 400%. The firm is expected to report its next quarterly earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.63) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.60). For the next year, analysts anticipate that the business will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the previous year, the business earned ($0.15) EPS.
Several equities analysts recently commented on ACHN shares. BidaskClub lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Chardan Capital decreased their price objective on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Maxim Group set a $7.00 price objective on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Robert W. Baird lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research report on Thursday, August 10th. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.29.
Shares of Achillion Pharmaceuticals (ACHN) traded down $0.13 during trading on Wednesday, hitting $3.43. 1,995,612 shares of the company traded hands, compared to its average volume of 1,654,996. Achillion Pharmaceuticals has a 52-week low of $2.95 and a 52-week high of $5.66.
A number of large investors have recently modified their holdings of the stock. Sarissa Capital Management LP acquired a new position in Achillion Pharmaceuticals in the 3rd quarter worth approximately $9,594,000. RTW Investments LP increased its holdings in Achillion Pharmaceuticals by 392.9% in the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock worth $35,201,000 after buying an additional 6,249,312 shares during the period. Dimensional Fund Advisors LP increased its holdings in Achillion Pharmaceuticals by 75.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after buying an additional 1,407,108 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Achillion Pharmaceuticals by 14.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 525,612 shares of the biopharmaceutical company’s stock worth $2,360,000 after buying an additional 68,271 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Achillion Pharmaceuticals in the 3rd quarter worth approximately $1,347,000. Institutional investors own 74.81% of the company’s stock.
WARNING: “Zacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) Will Announce Earnings of -$0.15 Per Share” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/11/18/zacks-brokerages-expect-achillion-pharmaceuticals-inc-achn-will-announce-earnings-of-0-15-per-share.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.